Kristen Fortney's most recent trade in BioAge Labs Inc. was a trade of 330,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioAge Labs Inc | Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 330,000 | 330,000 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Kristen Fortney | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.12 per share. | 13 Jan 2026 | 233,107 | 976,949 | - | 18.1 | 4,223,036 | Common Stock |
| BioAge Labs Inc | Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 530,000 | 530,000 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 708,044 | 708,044 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Kristen Fortney | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 424,827 | 424,827 | - | - | Stock Option (Right to Buy) |